-
[show abstract]
[hide abstract]
ABSTRACT: Catheter-associated urinary tract infection is the most common nosocomial infection in clinical settings. For bacteria ascending to the bladder the most common route is the extraluminal, but the intraluminal route also plays a role. For this reason, we compared two urinary closed system bags (CSB), one with a double and the other with a single non-return valve (NRV), in a laboratory setting in order to establish their ability to prevent or delay the ascent of bacteria from the drainage bag to the bladder.
The tests were performed in two microbiological laboratories (Copenhagen (C), Denmark and Freiburg (F), Germany). These were blinded to each other. A urinary tract model using artificial urine was set up. Two sets of ten drainage bags each with a double NRV (CSB A), and two sets of ten drainage bags each with a single NRV (CSB B) were inoculated with Escherichia coli (F: ATCC 25922; C: clinical strain). Daily samples were taken from two drainage ports on each system - one above the NRV (Port I), the other above the top of the artificial bladder (Port II). Time till E. coli was detected at the drainage ports (time to positivity) was measured. Colonization of the 'bladder' was defined as time to positivity at Port II.
No significant differences in time to positivity at Port I (median 9.0, range: 6-12 for CSB B vs median 9.5 days, range: 6-13 for CSB A) were observed between the two systems. However, substantial differences were seen between the two systems in time to positivity at Port II: Port II on the bladder model using CSB B became positive after a median of 14.0 days (range: 10-22), whereas Port II of the model using CSB A only became positive after 21.5 days (range: 13-24). This amounts to a highly significant difference of 7.5 days (p = 0.0001) in the mean.
Under laboratory conditions, colonization of the 'bladder' was significantly delayed when the CSB with a double NRV was used in comparison to the results obtained from the single NRV-system. Clinical trials should be conducted to investigate whether the urinary CSB with the double NRV has the ability to prevent (or to delay the onset of) catheter-associated urinary tract infection.
Infection 09/2006; 34(4):214-8. · 2.66 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: We investigated the antimicrobial activity of piperacillin-tazobactam versus piperacillin-sulbactam against common nosocomial pathogens (n = 565) isolated from intensive care patients. For Gram-positive bacteria, antimicrobial susceptibilities to the two piperacillin-beta-lactamase inhibitor combinations were almost identical. For Gram-negative bacteria, piperacillin-tazobactam exhibited greater activity against Escherichia coli and Proteus vulgaris than piperacillin-sulbactam. Both combinations, however, were equally effective against the other Enterobacteriaceae and Pseudomonas aeruginosa isolates. Piperacillin-sulbactam exhibited better antimicrobial activity against Acinetobacter baumannii. Our findings might prove important for the appropriate choice of antibiotic therapy with beta-lactam-beta-lactamase inhibitor combinations.
Clinical Microbiology and Infection 12/2003; 9(11):1128-32. · 4.54 Impact Factor
-
European Journal of Clinical Microbiology 12/2000; 19(11):888-91. · 2.86 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Penetration of teicoplanin into serum, heart valves, and subcutaneous and muscle tissues was determined in 22 patients undergoing open-heart surgery. Each patient received 12 mg of teicoplanin per kg of body weight as a 30-min intravenous infusion preoperatively. Within 10 h, serum concentrations of teicoplanin declined from 43.1 to 2.8 microg/ml. Teicoplanin concentrations in subcutaneous tissues reached their peak of 9.2 microg/g after 2 to 3 h and decreased slowly to 2.3 microg/g after 9 to 10 h. Concentrations in muscle decreased from 8.7 microg/g to nondetectable levels. Teicoplanin concentrations in cardiac valvular tissue reached their peak of 6.1 microg/g and decreased thereafter to 1.7 microg/g. Teicoplanin concentrations in heart valves were high enough to inhibit methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci, which are known to cause postoperative wound infections and infective endocarditis.
Antimicrobial Agents and Chemotherapy 12/1997; 41(11):2559-61. · 4.84 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In order to determine whether granulocyte colony-stimulating factor (G-CSF) can enhance the bactericidal activity of polymorphonuclear leukocytes (PMNL) in trauma patients, PMNL obtained from severely injured patients one or two days after trauma were incubated with G-CSF and Staphylococcus aureus for different periods of time. G-CSF at a concentration of 6000 units/ml significantly improved the antibacterial activity of PMNL in trauma patients (n = 10) and healthy volunteers (n = 12) during the incubation period of 180 min. No difference in the bactericidal function of PMNL could be found between severely injured patients and healthy donors.
European Journal of Clinical Microbiology 03/1993; 12(2):121-4. · 2.86 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Thirty-seven patients were given a single, 2-g intravenous bolus injection of flucloxacillin prior to open-heart surgery. Within 12 h, flucloxacillin concentrations in serum and heart valves declined from 125.2 to 4.4 micrograms/ml and from 16.5 to 3.7 micrograms/g, respectively. Concentrations in subcutaneous tissue and muscle were almost identical, declining from 14.7 or 14.2 micrograms/g to undetectable levels after 8 to 10 h.
Antimicrobial Agents and Chemotherapy 07/1988; 32(6):930-1. · 4.84 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Patients undergoing open-heart surgery were given an intravenous bolus injection of 2 g of ceftazidime as a single dose over a period of 5 min. Within 12 h, ceftazidime concentrations in serum declined from 55.8 to 3.9 mg/liter. Subcutaneous tissue concentrations of the drug decreased from 21.0 to 2.7 micrograms/g, and muscle concentrations decreased from 34.5 to 2.5 micrograms/g. Ceftazidime concentrations in cardiac valvular tissue were even higher than those in muscle or fat, declining from 37.4 to 6.3 micrograms/g within 10 h.
Antimicrobial Agents and Chemotherapy 06/1987; 31(5):813-4. · 4.84 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Penetration of vancomycin into serum, heart valves, subcutaneous tissue and muscle was determined in 33 adult patients undergoing open-heart surgery. Each patient received 15 mg/kg vancomycin as a 30-min intravenous infusion preoperatively. Within 6 h vancomycin plasma concentrations declined from 28.9 to 4.2 mg/l. Vancomycin concentrations decreased in subcutaneous tissue slowly and varied in muscle between 1.2 and 3.2 mg/kg, in subcutaneous tissue between 1.3 and 4.4 mg/kg and in heart valves between 2.3 and 4.2 mg/kg. Vancomycin concentrations in heart valves are high enough to inhibit most oxacillin-resistant Staphylococcus aureus, and coagulase-negative staphylococci causing postoperative wound infections and endocarditis.
Journal of Antimicrobial Chemotherapy 04/1987; 19(3):359-62. · 5.07 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The penetration of sulbactam plus ampicillin into lung tissue was studied in 15 patients undergoing thoracic surgery for pneumonectomy after the administration of 1 g of sulbactam plus 2 g of ampicillin as a 15 min intravenous short infusion. Ampicillin serum concentrations declined from 40.8 mg/l at 1 h to 18.8 mg/l 2-4 h after administration. Concomitant serum concentrations of sulbactam were 25.5 mg/l and 11.8 mg/l, respectively. In lung tissue, peak ampicillin concentrations of 35.6 mg/kg were reached 1.5 h after administration declining slowly to 26.8 mg/kg after 2-4 h. The respective sulbactam concentrations were 8.6 and 5.5 mg/kg. In our study sufficient sulbactam and ampicillin levels active against important pathogenic organisms causing community- and hospital-acquired respiratory tract infections have been achieved in lung tissue, suggesting that the combination sulbactam/ampicillin is suited for the treatment of most community- and hospital-acquired respiratory tract infections as well as for chemoprophylaxis and treatment of postoperative lung infections after thoracic surgery.
Infection 18(5):307-9. · 2.66 Impact Factor
-
Infection 16(4):250. · 2.66 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Gram-positive bacteria are increasingly found to be causative pathogens in nosocomial infections, and the occurrence of vancomycin resistance in enterococci as well as staphylococci has prompted the investigation of alternative antimicrobial agents active against these strains. Everninomycin, a new oligosaccharide antibiotic, has excellent in vitro activity against gram-positive bacteria, including those resistant to vancomycin. However, avilamycin, a related compound, has been used in Europe as a growth promoter in animal food for years and concern has been raised that cross-resistance in clinical isolates may arise.
We studied a collection of 268 nosocomial gram-positive isolates from intensive care unit patients with nosocomial pneumonia, urinary tract infection and sepsis, using standard in vitro susceptibility testing.
It could be shown that all species tested were exquisitely sensitive to everninomycin (MIC(90) of 0.38 microg/ml for Staphylococcus aureus, 0.5 microg/ml for enterococci and 0.75 microg/ml for coagulase-negative staphylococci). Furthermore, no difference could be observed between methicillin-resistant and methicillin-sensitive S. aureus or between Enterococcus faecium and Enterococcus faecalis.
These results suggest that everninomycin is a promising antibiotic for the treatment of nosocomial infections in intensive care unit patients and that the use of a related substance as an additive in animal food has not yet promoted resistance in clinical isolates.
Chemotherapy 47(1):15-8. · 1.82 Impact Factor
